← Back to patent-cliff list
ALN-4324
Tier C — Watch / tradeALN-4324
Alnylam Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：GRB14
Indications (approved)：Overweight, Type 2 diabetes, Obesity
Regional status
US
Phase II
2025-03-03
EU
Phase II
2025-03-03
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ALN-4324?
Approved indications include: Overweight, Type 2 diabetes, Obesity.
When does the ALN-4324 patent expire?
No public expiry year is available for ALN-4324 yet; this page updates once verified.
How do I get a quote for ALN-4324 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01